伊朗婴幼儿及儿童抗百日咳抗体水平评估:是否应将无细胞百日咳疫苗加强针纳入免疫规划?
该横断面研究纳入1012名伊朗婴幼儿及儿童,采用商业ELISA试剂盒检测抗百日咳IgG抗体。≤2月龄婴儿抗体阳性率仅15%,7-18月龄和19-36月龄最高(63%和66%),37月龄后降至45%-47%。接种后时间与抗体水平显著相关(p=0.005),作者强调新生儿免疫不足及年长儿童免疫衰减问题。
要点
- ≤2月龄婴儿抗百日咳抗体阳性率仅15%,多数呈阴性。
- 抗体阳性率在7-36月龄达高峰(63%-66%),37月龄后降至45%-47%。
- 接种后时间与抗百日咳IgG水平显著相关(p=0.005)。
核心结论
- 研究显示抗百日咳抗体阳性率偏低,尤其≤2月龄婴儿多数呈阴性,凸显新生儿因免疫不足而易感百日咳,作者强调亟需有效的母体疫苗接种策略。
- 作者观察到36月龄后抗百日咳IgG水平下降,对年长儿童免疫衰减表示担忧。
- 作者认为持续研究对评估加强针长期效果和制定最佳接种策略至关重要。
研究设计与样本
- 横断面研究,纳入1012名伊朗婴幼儿及儿童。
- 血清样本于-20°C保存至分析,采用商业ELISA试剂盒检测抗百日咳IgG抗体。
- 收集人口学特征、百白破全程细胞百日咳(DTwP)疫苗接种状态及接种后时间。
主要发现
- 参与者中位年龄35月龄(IQR:9-72月龄)。
- ≤2月龄婴儿抗百日咳抗体阳性率为15%,3-4月龄组为28%,5-6月龄组为55%。
- 7-18月龄组阳性率63%,19-36月龄组66%,37-72月龄组降至45%,>72月龄组为47%。
- 接种后时间与抗百日咳IgG水平之间存在显著关系(p=0.005)。
临床怎么用
- 作者强调亟需有效的母体疫苗接种策略以保护新生儿。
- 作者认为持续研究对评估加强针长期效果和制定最佳接种策略至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The prevalence of anti-pertussis antibodies among infants and children in Iran has not been thoroughly investigated. Given that recommendations for booster vaccines are based on national disease epidemiology, we aimed to evaluate the seroprevalence of pertussis antibodies among infants and children in an Iranian referral hospital. MATERIALS AND METHODS: A total of 1012 infants and children were included in the study. Serum samples were stored at -20 °C until analysis. Demographic characteristics of patients, including age, sex, trivalent diphtheria, tetanus, and whole-cell pertussis (DTwP) vaccination status, and time since DTwP vaccination were collected. Anti-pertussis IgG antibodies were measured using a commercial ELISA kit. RESULTS: In this cross-sectional study, the median age of the participants was 35 months (IQR:9-72 months). In infants ≤2 months, only 15 % had positive anti-pertussis antibodies. This increased to 28 % in the 3 to 4 months group and 55 % in the 5 to 6 months group. The highest positivity rates (63 % and 66 %) were seen in the 7 to 18 months and 19 to 36 months age groups, respectively. Positivity declined to 45 % in the 37 to 72 months group, and 47 % in those over 72 months. A significant relationship was found between the time elapsed since vaccination and anti-pertussis IgG levels (p = 0.005). CONCLUSION: Our study highlights a concerning prevalence of low anti-pertussis, especially among infants aged ≤2 months, where the majority displayed negative results. This situation underscores the vulnerability of newborns to pertussis due to insufficient immunity and emphasizes the urgent need for effective maternal vaccination strategies. Additionally, we observed a decline in anti-pertussis IgG levels after 36 months, raising concerns about waning immunity in older children. Continued research is crucial to evaluate the long-term efficacy of booster vaccines and to develop optimal vaccination strategies to protect infants and children from pertussis.
引用
- Pourakbari B, Mahmoudi S, Sajedi Moghaddam S, et al. Evaluation of anti-Pertussis antibody levels in Iranian infants and children: Is it time to include booster acellular Pertussis Vaccines in the immunization schedule? Vaccine. 2025. PMID: 39823849. doi:10.1016/j.vaccine.2025.126736
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。